Answers are grounded in this paper and cite their sources.
Leukemia accounts for ~3.1% of cancer burden in the world and there are no reliable noninvasive markers for subtyping and monitoring. The paper sought to characterize hematological, hepatic, renal, and cytokine profiles across the four major leukemia subtypes, quantify serum bisphenol A along with the profiling of three circulating microRNAs (miR‐34a, miR‐17, miR‐155), and integrate bisphenol A and microRNAs data into a unified biomarker framework using correlation and ROC analyses. The study was a case–control study, with 100 participants (80 cases and 20 healthy controls). The expression level of microRNAs was quantified using the RT‐qPCR technique (2 −ΔΔCt method, normalized to miR‐16‐5p). Mann–Whitney U , Kruskal–Wallis and binormal ROC analysis were used in the statistics. The biochemical characteristics of each of the subtypes were different: acute leukemias (ALL, AML) had severe cytopenias, coagulopathy, hepatic and renal impairment, and peak cytokine activity; CLL had extreme lymphocytosis and the highest β2‐microglobulin; CML had marked leukocytosis, thrombocytosis, and elevated vitamin B12. Serum bisphenol A was significantly elevated in all subtypes versus controls (6.12–8.44 vs. 2.30 ng/mL, p < 0.0001), with ROC AUCs of 0.770–0.842. miR‐34a was significantly suppressed in all the subtypes and miR‐17 and miR‐155 were constantly upregulated, with miRNA ROC AUCs ranging from 0.718 to 1.000 (91.7% excellent, ≥ 0.90). BPA was increased with IL‐6, ferritin and LDH and decreased with miR‐34a. A first cross‐subtype, cross‐platform analysis of all four leukemia subtypes suggests that a combined bisphenol A and miRNA signature is a promising noninvasive approach to leukemia detection, subtyping, and monitoring.
No takes yet. Share an insight, caveat, or question.
Sulaiman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: